Towards a prophylactic treatment of HPA-related foetal and neonatal alloimmune thrombocytopenia

Current Opinion in Hematology

Volumn 19, Issue 6, 2012, Pages 469-474

  Kjeldsen Kragh, Jens ^a   Ni, Heyu ^b   Skogen, Bjørn ^c  

^a Lund University   (Sweden)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

anti HPA 1 antibodies; clinical trial; foetal and neonatal alloimmune thrombocytopenia; hyperimmune immunoglobulin G; immunoprophylaxis

Indexed keywords

ALLOANTIBODY; HUMAN PLATELET ANTIGEN 1A ANTIBODY; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN G; P SELECTIN GLYCOPROTEIN LIGAND 1; PATTERN RECOGNITION RECEPTOR; RANTES; RHESUS D ANTIBODY; THROMBOCYTE ANTIBODY; THROMBOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIBODY SCREENING; ANTIGEN PRESENTING CELL; BLOOD SAMPLING; DRUG SAFETY; HEMOLYTIC ANEMIA; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOPROPHYLAXIS; NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; NONHUMAN; NORWAY; PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; TOXICITY; TRANSFUSION RELATED ACUTE LUNG INJURY; UNSPECIFIED SIDE EFFECT;

ANTIGENS, HUMAN PLATELET; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFANT, NEWBORN; ISOANTIBODIES; MATERNAL-FETAL EXCHANGE; PREGNANCY; THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE;

EID: 84868212709     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328358f86c     Document Type: Review

References (35)

1. Bowman JM. RhD hemolytic disease of the newborn. N Engl J Med 1998; 339:1775-1777.
2. Clarke CA, Finn R, McConnell RB, Sheppard PM. The protection afforded by ABO incompatability against erythroblastosis due to rhesus anti-D. Int Arch Allergy 1958; 13:380.
3. Prevention of Rh-haemolytic disease: results of the clinical trial. A combined study from centres in England and Baltimore. Br Med J 1966; 2:907-914.
4. Prevention of primary Rh immunization: first report of the Western Canadian trial, 1966-1968. Can Med Assoc J 1969; 100:1021-1024.
5. Pollack W, Gorman JG, Freda VJ, et al. Results of clinical trials of RhoGAM in women. Transfusion 1968; 8:151-153.
6. Crowther C, Middleton P. Anti-D administration after childbirth for preventing Rhesus alloimmunisation. Cochrane Database Syst Rev 2000:CD000021.
7. Moulinier J, editor. Iso-immunisation maternelle antiplaquettaire et purpura né o-natal. Le système de groupe plaquettaire 'Duzo'. In: Proceedings of the 6th Congress of the European Society of Hematology; August 1957; Copenhagen.
8. Murphy MF, Bussel JB. Advances in the management of alloimmune thrombocytopenia. Br J Haematol 2007; 136:366-378.
9. Kjeldsen-Kragh J, Killie MK, Tomter G, et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood 2007; 110:833-839.
10. Kamphuis MM, Paridaans N, Porcelijn L, et al. Screening in pregnancy for fetal or neonatal alloimmune thrombocytopenia: systematic review. BJOG 2010; 117:1335-1343.
11. Spencer JA, Burrows RF. Feto-maternal alloimmune thrombocytopenia: a literature review and statistical analysis. Aust N Z J Obstet Gynaecol 2001; 41:45-55.
12. Burrows RF, Kelton JG. Fetal thrombocytopenia and its relation to maternal thrombocytopenia. N Engl J Med 1993; 329:1463-1466.
13. de Moerloose P, Boehlen F, Extermann P, Hohfeld P. Neonatal thrombocytopenia: incidence and characterization of maternal antiplatelet antibodies by MAIPA assay. Br J Haematol 1998; 100:735-740.
14. Dreyfus M, Kaplan C, Verdy E, et al. Frequency of immune thrombocytopenia in newborns: a prospective study. Immune Thrombocytopenia Working Group. Blood 1997; 89:4402-4406.
15. Panzer S, Auerbach L, Cechova E, et al. Maternal alloimmunization against fetal platelet antigens: a prospective study. Br J Haematol 1995; 90:655-660.
16. Sainio S, Jarvenpaa AL, Renlund M, et al. Thrombocytopenia in term infants: a population-based study. Obstet Gynecol 2000; 95:441-446.
17. Uhrynowska M, Niznikowska-Marks M, Zupanska B. Neonatal and maternal thrombocytopenia: incidence and immune background. Eur J Haematol 2000; 64:42-46.
18. Bertrand G, Drame M, Martageix C, Kaplan C. Prediction of the fetal status in noninvasive management of alloimmune thrombocytopenia. Blood 2011; 117:3209-3213.
19. Mueller-Eckhardt C, Kiefel V, Grubert A, et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1989; 1:363-366.
20. Gruel Y, Boizard B, Daffos F, et al. Determination of platelet antigens and glycoproteins in the human fetus. Blood 1986; 68:488-492.
21. Kiefel V, Konig C, Kroll H, Santoso S. Platelet alloantibodies in transfused patients. Transfusion 2001; 41:766-770.
22. Zhou Y, Fisher SJ, Janatpour M, et al. Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion? J Clin Invest 1997; 99:2139-2151.
23. Johansen M, Redman CW, Wilkins T, Sargent IL. Trophoblast deportation in human pregnancy-its relevance for preeclampsia. Placenta 1999; 20:531-539.
24. Huppertz B, Kingdom J, Caniggia I, et al. Hypoxia favours necrotic versus apoptotic shedding of placental syncytiotrophoblast into the maternal circulation. Placenta 2003; 24:181-190.
25. Eastlake J, Kumpel B. Effects of placental microparticles and platelets on in vitro cytokine profiles and their ability to cause an anti-HPA-1a antibody response in vivo. J Transfus Med 2012; 2:65.
26. Kumpel BM, Sibley K, Jackson DJ, et al. Ultrastructural localization of glycoprotein IIIa (GPIIIa, beta 3 integrin) on placental syncytiotrophoblast microvilli: implications for platelet alloimmunization during pregnancy. Transfusion 2008; 48:2077-2086.
27. Turner ML, Bessos H, Fagge T, et al. Prospective epidemiologic study of the outcome and cost-effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti-HPA-1a. Transfusion 2005; 45:1945-1956.
28. Killie MK, Husebekk A, Kjeldsen-Kragh J, Skogen B. A prospective study of maternal anti-HPA 1a antibody level as a potential predictor of alloimmune thrombocytopenia in the newborn. Haematologica 2008; 93:870-877.
29. Ni H, Chen P, Spring CM, et al. A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy. Blood 2006; 107:2976-2983.
30. Tiller H, Killie MK, Chen P, et al. Toward a prophylaxis against fetal and neonatal alloimmune thrombocytopenia: induction of antibody-mediated immune suppression and prevention of severe clinical complications in a murine model. Transfusion 2012; 52:1446-1457.
31. Brinc D, Denomme GA, Lazarus AH. Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn: what can we learn from rodent models? Curr Opin Hematol 2009; 16:488-496.
32. Passacquale G, Vamadevan P, Pereira L, et al. Monocyte-platelet interaction induces a pro-inflammatory phenotype in circulating monocytes. PLoS One 2011; 6:e25595.
33. Heddle NM, Soutar RL, O'Hoski PL, et al. A prospective study to determine the frequency and clinical significance of alloimmunization posttransfusion. Br J Haematol 1995; 91:1000-1005.
34. Hoeltge GA, Domen RE, Rybicki LA, Schaffer PA. Multiple red cell transfusions and alloimmunization. Experience with 6996 antibodies detected in a total of 159 262 patients from 1985 to 1993. Arch Pathol Lab Med 1995; 119:42-45.
35. Dettke M, Dreer M, Hocker P, Panzer S. Human platelet antigen-1a antibodies induce the release of the chemokine RANTES from human platelets. Vox Sang 2001; 81:199-203.